The Impact of Cannabis Use on Clinical Outcomes in Recent Onset Psychosis

Schizophrenia Bulletin

Volumn 41, Issue 2, 2015, Pages 382-390

  Barrowclough, Christine ^a   Gregg, Lynsey ^a   Lobban, Fiona ^b   Bucci, Sandra ^a   Emsley, Richard ^c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b LANCASTER UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

cannabis; dual diagnosis; psychosis; substance use

Indexed keywords

CHLORPROMAZINE;

ADULT; ALCOHOL ABUSE; ALCOHOLISM; ANXIETY; ARTICLE; CANNABIS ADDICTION; CANNABIS USE; DEPRESSION; EMOTIONAL DISORDER; FEMALE; HOSPITAL ADMISSION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; OUTCOME ASSESSMENT; POSITIVE SYNDROME; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; YOUNG ADULT; ADOLESCENT; ADVERSE EFFECTS; CANNABIS SMOKING; CHEMICALLY INDUCED; COGNITIVE THERAPY; COMORBIDITY; FOLLOW UP; MARIJUANA ABUSE; MOTIVATIONAL INTERVIEWING; PATHOPHYSIOLOGY; PROCEDURES; PSYCHIATRIC DIAGNOSIS; PSYCHOTIC DISORDERS;

ADOLESCENT; ADULT; ANXIETY; COGNITIVE THERAPY; COMORBIDITY; DEPRESSION; DIAGNOSIS, DUAL (PSYCHIATRY); FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MARIJUANA ABUSE; MARIJUANA SMOKING; MOTIVATIONAL INTERVIEWING; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHOTIC DISORDERS; YOUNG ADULT;

EID: 84940834878     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbu095     Document Type: Article

References (41)

1. Koskinen J, Löhönen J, Koponen H, Isohanni M, Miettunen J. Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophr Bull. 2010;36:1115-1130.
2. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370:319-328.
3. Large M, Sharma S, Compton MT, Slade T, Nielssen O. Cannabis use and earlier onset of psychosis: a systematic meta-analysis. Arch Gen Psychiatry. 2011;68:555-561.
4. Zammit S, Moore TH, Lingford-Hughes A, et al. Effects of cannabis use on outcomes of psychotic disorders: systematic review. Br J Psychiatry. 2008;193:357-363.
5. Wade D, Harrigan S, Edwards J, Burgess PM, Whelan G, McGorry PD. Substance misuse in first-episode psychosis: 15-month prospective follow-up study. Br J Psychiatry. 2006;189:229-234.
6. Hides L, Dawe S, Kavanagh DJ, Young RM. Psychotic symptom and cannabis relapse in recent-onset psychosis. Prospective study. Br J Psychiatry. 2006;189:137-143.
7. Horcajadas A, Romero S, Calo J. Relevance of drug use in clinical manifestations of schizophrenia [Spanish]. Actas Esp Psiquiatr. 2002;30:65-73.
8. Martinez-Arevalo MJ, Calcedo-Ordoñez A, Varo-Prieto JR. Cannabis consumption as a prognostic factor in schizophrenia. Br J Psychiatry. 1994;164:679-681.
9. Caspari D. Cannabis and schizophrenia: results of a followup study. Eur Arch Psychiatry Clin Neurosci. 1999;249:45-49.
10. Grech A, Van Os J, Jones PB, Lewis SW, Murray RM. Cannabis use and outcome of recent onset psychosis. Eur Psychiatry. 2005;20:349-353.
11. Degenhardt L, Tennant C, Gilmour S, et al. The temporal dynamics of relationships between cannabis, psychosis and depression among young adults with psychotic disorders: findings from a 10-month prospective study. Psychol Med. 2007;37:927-934.
12. Clausen L, Hjorthøj CR, Thorup A, et al. Change in cannabis use, clinical symptoms and social functioning among patients with first-episode psychosis: a 5-year follow-up study of patients in the OPUS trial. Psychol Med. 2014;44:117-126.
13. Stone JM, Fisher HL, Major B, et al.; MiData Consortium. Cannabis use and first-episode psychosis: relationship with manic and psychotic symptoms, and with age at presentation. Psychol Med. 2014;44:499-506.
14. Foti DJ, Kotov R, Guey LT, Bromet EJ. Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. Am J Psychiatry. 2010;167:987-993.
15. Stirling J, Lewis S, Hopkins R, White C. Cannabis use prior to first onset psychosis predicts spared neurocognition at 10-year follow-up. Schizophr Res. 2005;75:135-137.
16. Barrowclough C, Emsley R, Eisner E, Beardmore R, Wykes T. Does change in cannabis use in established psychosis affect clinical outcome? Schizophr Bull. 2013;39:339-348.
17. Faber G, Smid HG, Van Gool AR, Wunderink L, van den Bosch RJ, Wiersma D. Continued cannabis use and outcome in first-episode psychosis: data from a randomized, openlabel, controlled trial. J Clin Psychiatry. 2012;73:632-638.
18. van Dijk D, Koeter MW, Hijman R, Kahn RS, van den Brink W. Effect of cannabis use on the course of schizophrenia in male patients: a prospective cohort study. Schizophr Res. 2012;137:50-57.
19. Mullin K, Gupta P, Compton MT, Nielssen O, Harris A, Large M. Does giving up substance use work for patients with psychosis? A systematic meta-analysis. Aust N Z J Psychiatry. 2012;46:826-839.
20. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc. 1964;86:1646-1647.
21. Di Forti M, Morgan C, Dazzan P, et al. High-potency cannabis and the risk of psychosis. Br J Psychiatry. 2009;195:488-491.
22. Di Forti M, Sallis H, Allegri F, et al. Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in Cannabis Users [published online ahead of print December 17, 2013]. Schizophr Bull. doi: 10.1093/schbul/sbt181.
23. Crippa JA, Zuardi AW, Martín-Santos R, et al. Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol. 2009;24:515-523.
24. Lev-Ran S, Roerecke M, Le Foll B, George TP, McKenzie K, Rehm J. The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies. Psychol Med. 2013:1-14.
25. Barrowclough C, Marshall M, Gregg L, Fitzsimmons M, Tomenson B, Warburton J, Lobban F. A phase specific psychological therapy for people with problematic cannabis use following a first episode of psychosis: A Randomised Controlled Trial. Psychol Med. In press.
26. First MB, Spitzer RL, Gibbon M, Williams JB. Structured Clinical Interview for DSM-IV Axis I Disorders-Clinician Version (SCID-CV). American Psychiatric Press; 1997.
27. Norberg MM, Mackenzie J, Copeland J. Quantifying cannabis use with the timeline followback approach: a psychometric evaluation. Drug Alcohol Depend. 2012;121:247-252.
28. Barrowclough C, Haddock G, Wykes T, et al. Integrated motivational interviewing and cognitive behavioural therapy for people with psychosis and comorbid substance misuse: randomised controlled trial. BMJ. 2010;341:c6325.
29. Hjorthoj CR, Fohlmann A, Larsen AM, Gluud C, Arendt M, Nordentoft M. Specialized psychosocial treatment plus treatment as usual (TAU) versus TAU for patients with cannabis use disorder and psychosis: the CapOpus randomized trial. Psychol Med. 2012:1-12.
30. Hardwick S, King LA. Home Office Cannabis Potency Study 2008. St Albans: Home Office Scientific Development Branch; 2008.
31. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
32. APA. Diagnostic and Statistical Manual for Mental Disorders. 4th ed. Washington, DC: American psychiatric Association; 1994.
33. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988;56:893-897.
34. Addington D, Addington J, Matickatyndale E. Assessing Depression in Schizophrenia - the Calgary Depression Scale. Brit J Psychiat. 1993;163:39-44.
35. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13:177-183.
36. Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res. 2000;42:241-247.
37. Degenhardt L, Hall W, Lynskey M. Exploring the association between cannabis use and depression. Addiction. 2003;98:1493-1504.
38. Patton GC, Coffey C, Carlin JB, Degenhardt L, Lynskey M, Hall W. Cannabis use and mental health in young people: cohort study. BMJ. 2002;325:1195-1198.
39. van Laar M, van Dorsselaer S, Monshouwer K, de Graaf R. Does cannabis use predict the first incidence of mood and anxiety disorders in the adult population? Addiction. 2007;102:1251-1260.
40. D'Souza DC, Perry E, MacDougall L, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology. 2004;29:1558-1572.
41. D'Souza DC, Abi-Saab WM, Madonick S, et al. Delta-9- tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry. 2005;57:594-608.